Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Genomics, Proteomics, and Target Discovery

Abstract A206: Clinically relevant perspectives of the clonal nature of cancer

Michael T. Barrett, Stephanie Savage, Elizabeth Lenkiewicz, Jeff Kiefer, Donald Chow, Holly Yin, Christian Ruiz, Lukas Bubendorf, Spyro Mousses, Michael J. Demeure and Daniel Von Hoff
Michael T. Barrett
1 TGen, Scottsdale, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie Savage
1 TGen, Scottsdale, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Lenkiewicz
1 TGen, Scottsdale, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeff Kiefer
1 TGen, Scottsdale, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald Chow
1 TGen, Scottsdale, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly Yin
1 TGen, Scottsdale, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Ruiz
2 Institute of Pathology, Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lukas Bubendorf
2 Institute of Pathology, Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Spyro Mousses
1 TGen, Scottsdale, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Demeure
1 TGen, Scottsdale, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Von Hoff
1 TGen, Scottsdale, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.TARG-09-A206 Published December 2009
  • Article
  • Info & Metrics
Loading
Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA

Abstract

It has been hypothesized and subsequently shown that tumors arise as a result of an acquired genomic instability and the subsequent evolution of clonal populations of neoplastic cells. Thus the pattern and behavior of distinct genomically aberrant clones may underlie multiple clinical phenotypes in a variety of cancers. A fundamental hypothesis of cancer genome studies is that genes and cellular networks targeted by selected aberrations represent vulnerabilities that can be exploited for effective personalized therapies. However, the heterogeneity of neoplastic cells and the presence of admixtures of genomically normal cells make it difficult to comprehensively define cancer genomes in patients in vivo. By applying single parameter and multi parameter DNA content based flow cytometry of nuclei to isolate clonal populations from solid tumor biopsies, and coupling this strategy with array CGH, we obtained high definition genomic profiles of clonal populations from pancreatic adenocarcinomas (PA), adrenal cortical carcinomas (ACC), and prostate carcinomas (PC). The genomes of clonal populations in these disparate cancers have distinct patient‐specific sets of aberrations with clinical relevance. For example, our clonal analyses detected unique gene‐specific homozygous deletions converging on NOTCH signaling and multiple focal amplicons that target cell migration in PA, distinguished divergent clones within single biopsies, and identified genomic aberrations specific to therapeutically sensitive and resistant clones arising during the evolution of androgen independent metastatic PC. Application of these technologies in combination with next generation sequencing allows for elucidation of the unique clonal identities of cancer genomes in patients in vivo, which in turn can help guide diagnoses and tailor approaches to treatment.

Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A206.

  • Copyright © 2009, American Association for Cancer Research
Previous
Back to top
Molecular Cancer Therapeutics: 8 (12 Supplement)
December 2009
Volume 8, Issue 12 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A206: Clinically relevant perspectives of the clonal nature of cancer
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A206: Clinically relevant perspectives of the clonal nature of cancer
Michael T. Barrett, Stephanie Savage, Elizabeth Lenkiewicz, Jeff Kiefer, Donald Chow, Holly Yin, Christian Ruiz, Lukas Bubendorf, Spyro Mousses, Michael J. Demeure and Daniel Von Hoff
Mol Cancer Ther December 10 2009 (8) (12 Supplement) A206; DOI: 10.1158/1535-7163.TARG-09-A206

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A206: Clinically relevant perspectives of the clonal nature of cancer
Michael T. Barrett, Stephanie Savage, Elizabeth Lenkiewicz, Jeff Kiefer, Donald Chow, Holly Yin, Christian Ruiz, Lukas Bubendorf, Spyro Mousses, Michael J. Demeure and Daniel Von Hoff
Mol Cancer Ther December 10 2009 (8) (12 Supplement) A206; DOI: 10.1158/1535-7163.TARG-09-A206
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Genomics, Proteomics, and Target Discovery

  • Abstract PL02-03: The zinc-finger degrome
  • Abstract CN03-01: Functional genomics approaches to the discovery of paralog dependencies in cancer
  • Abstract CN03-02: Functional genomics approaches to identify targetable dependencies in cancer cells
Show more Genomics, Proteomics, and Target Discovery

Genomics, Proteomics, and Target Discovery: Poster Presentations

  • Abstract A201: Mutation profiling and prognostic value of BRAF, HRAS, KRAS, MET, NRAS, PIK3CA, KRASG12V in colon cancer: Results from NSABP C‐07
  • Abstract A209: Comprehensive analysis of the MET protooncogene promoter regulation
  • Abstract A202: RNAi as a tool to identify novel molecular vulnerabilities in myeloid leukemias
Show more Genomics, Proteomics, and Target Discovery: Poster Presentations
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement